LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFbeta derived tetrapeptide and a competitive TGF-beta1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-beta1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier[1][2].
Molecular Weight:
572.62
Purity:
99.21
CAS Number:
[2828433-17-4]
Formula:
C23H43F3N6O7
Target:
TGF-beta Receptor
Application Notes:
Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
